Enoxaparin can be used safely in patients with severe thrombocytopenia due to intensive chemotherapy regimens

被引：53

作者：

Herishanu, Y ^{[1
]}

Misgav, M ^{[1
]}

Kirgner, I ^{[1
]}

Ben-Tal, O ^{[1
]}

Eldor, A ^{[1
]}

Naparstek, E ^{[1
]}

机构：

[1] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Dept Hematol, IL-69978 Tel Aviv, Israel

来源：

LEUKEMIA & LYMPHOMA | 2004年 / 45卷 / 07期

关键词：

thrombocytopenia; low molecular weight heparin; enoxaparin; catheter related central vein thrombosis; intensive chemotherapy regimen;

D O I：

10.1080/10428190410001663671

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Treatment with intensive chemotherapy regimens is frequently complicated by severe thrombocytopenia. During the period of severe thrombocytopenia, anticoagulant treatment is not uncommonly indicated for thromboembolic events or thromboprophylaxis in these patients. We report 10 hematological patients treated with intensive chemotherapy protocols that were anticoagulated with enoxaparin for catheter related central venous thrombosis and thromboprophylaxis. During the period of severe thrombocytopenia the dosages of enoxaparin were reduced and no major bleeding occurred. Based on our experience we suggest that reduced dosages of low molecular weight heparins may be used relatively safely during transient severe thrombocytopenia.

引用

页码：1407 / 1411

页数：5

共 18 条

[1] Thrombotic complications of central venous catheters in cancer patients [J].

Bona, RD .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1999, 25 (02) :147-155

[2]

CARTER CJ, 1982, BLOOD, V59, P1239

[3] Central venous catheter-related complications in patients with hematological malignancies: A retrospective analysis of risk factors and prophylactic measures [J].

Cortelezza, A ;

Fracchiolla, NS ;

Maisonneuve, P ;

Moia, M ;

Luchesini, C ;

Ranzi, ML ;

Monni, P ;

Pasquini, MC ;

Lambertenghi-Deliliers, G .

LEUKEMIA & LYMPHOMA, 2003, 44 (09) :1495-1501

[4] Thrombin-induced platelet activation is inhibited by high- and low-molecular-weight heparin [J].

De Candia, E ;

De Cristofaro, R ;

Landolfi, R .

CIRCULATION, 1999, 99 (25) :3308-3314

[5]

DRAKOS PE, 1992, CANCER-AM CANCER SOC, V70, P1895, DOI 10.1002/1097-0142(19921001)70:7<1895::AID-CNCR2820700715>3.0.CO

[6]

2-I

[7] Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study [J].

Forrest, DL ;

Thompson, K ;

Dorcas, VG ;

Couban, SH ;

Pierce, R .

BONE MARROW TRANSPLANTATION, 2003, 31 (12) :1143-1149

[8] The treatment and outcome of cancer patients with thromboses on central venous catheters [J].

Frank, DA ;

Meuse, J ;

Hirsch, D ;

Ibrahim, JG ;

van den Abbeele, AD .

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2000, 10 (03) :271-275

[9] PROTAMINE NEUTRALIZATION OF INTRAVENOUS AND SUBCUTANEOUS LOW-MOLECULAR-WEIGHT HEPARIN (TINZAPARIN, LOGIPARIN(TM)) - AN EXPERIMENTAL INVESTIGATION IN HEALTHY-VOLUNTEERS [J].

HOLST, J ;

LINDBLAD, B ;

BERGQVIST, D ;

GARRE, K ;

NIELSEN, H ;

HEDNER, U ;

OSTERGAARD, PB .

BLOOD COAGULATION & FIBRINOLYSIS, 1994, 5 (05) :795-803

[10] THE EFFECT OF MOLECULAR-WEIGHT ON HEPARIN BINDING TO PLATELETS [J].

HORNE, MK ;

CHAO, ES .

BRITISH JOURNAL OF HAEMATOLOGY, 1990, 74 (03) :306-312

← 1 2 →